Atorvastatin calcium: PLACE IN THERAPY(7)
In some patients with homozygous FH, treatment includes LDL apheresis . In severe cases, adjunctive drug therapy is often tried in attempts to further lower LDL-C levels. Clinical data with atorvastatin have shown that at high doses (up to 80 mg/day), significant reductions in LDL-C were observed in such patients, including in some patients with absent LDL receptor function . Atorvastatin may thus be a useful agent as adjunctive therapy with LDL aphere-sis in patients with homozygous FH. asthma inhalers
Atorvastatin is available in Canada in 10 mg, 20 mg or 40 mg tablets (bottles of 90 tablets) . List prices are as follows: $1.60/10 mg tablet; $2.00/20 mg tablet; $2.15/40 mg tablet.
Pharmacoeconomic analyses of lipid lowering therapies, including HMG-CoA reductase inhibitors, have shown these to be cost effective for secondary prevention of CAD . Pharmacoeconomic evidence of lipid lowering therapy in primary prevention of CAD is less common . Although, to date, no pharmacoeconomic studies have been conducted with atorvastatin, inclusion ofatorvastatin in phar-macoeconomic models evaluating lifetime cost effectiveness in primary or secondary prevention has been analyzed. These data suggested atorvastatin to be the most cost effective treatment compared with the other available HMG-CoA reductase inhibitors versus no therapy. In a primary prevention model, at usual starting doses, atorvastatin provided the lowest cost per life year gained for both men and women . In a separate analysis of HMG-CoA reductase inhibitors in secondary prevention of MI, atorvastatin provided the lowest cost per year of life saved compared with other HMG-CoA reductase inhibitors.